NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » Company News » Sera raises $100m to commercialise PreTRM test for premature birth risk » biomarker

Sera raises $100m to commercialise PreTRM test for premature birth risk

Sera Prognostics will use funds to advance the commercialisation of its blood-based biomarker test called PreTRM test. (Credit: Ahmad Ardity from Pixabay)

NS Medical Devices is using cookies

Sera Prognostics will use funds to advance the commercialisation of its blood-based biomarker test called PreTRM test. (Credit: Ahmad Ardity from Pixabay)

Related Article

Biggest players in the global wound care market

RECOMMENDED COMPANIES

MOST READ

Exo introduces new cardiac and lung AI applications on Exo Iris

Front Line Medical gets CE Mark for COBRA-OS occlusion device

FDA clears Epitel’s REMI EEG monitoring system and REMI Vigilenz AI platform

GE HealthCare, Elekta expand collaboration to boost radiation therapy

Philips secures FDA 510(k) approval for its Zenition 30 mobile C-arm

Recommended Whitepaper